DGX stock forecast, quote, news & analysis

Key Takeaways

• DGX stock rose +0.3% over the last 30 days, showing relative stability amid anticipation for upcoming quarterly earnings.
• The stock gained +3.2% over the past quarter, supported by a strong Q4 earnings beat and dividend increase.
• Key drivers include robust Q4 revenue growth of 7.1%, positive analyst sentiment with targets around $218, and resilient demand in diagnostics.
• Upcoming Q1 earnings and macroeconomic healthcare trends remain critical influencers for future price movement.

Quest Diagnostics (DGX) Company Overview and Market Position

Quest Diagnostics Incorporated (DGX) is a leading provider of diagnostic information services, empowering people to achieve better health outcomes through clinical laboratory testing. The company's core business model revolves around routine, non-routine, and advanced diagnostics, serving physicians, hospitals, and consumers across the United States. Operating in the competitive healthcare diagnostics industry, DGX holds a strong market position alongside peers like LH, benefiting from steady demand for testing services amid aging populations and chronic disease prevalence. Its solid fundamentals, including consistent revenue growth and operational efficiency, underpin recent stock resilience despite sector volatility.

Quest Diagnostics (DGX) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, from a closing price of approximately $194.41 on March 20 to $195.02 on April 17, DGX stock advanced +0.3%, reflecting a relatively flat, range-bound movement with low volatility ahead of earnings. In contrast, the past quarter saw a steadier uptrend, rising +3.2% from $188.95 on January 20 to the recent $195.02 close, driven by post-earnings momentum before a minor consolidation phase.

What Drove DGX Stock Price in the Last 30 Days

DGX stock's modest +0.3% gain over the past 30 days was influenced by anticipation surrounding the upcoming Q1 2026 earnings release on April 21, with analysts forecasting $2.81 billion in revenue and $2.34 EPS. The ex-dividend date on April 6 contributed to minor pressure, as shares adjusted post-payout of the increased quarterly dividend. Recent analyst actions, including Evercore ISI's price target adjustment to $210, supported sentiment amid broader market volatility. Sector trends in healthcare diagnostics provided a stable backdrop, though DGX slightly underperformed peers on select days.

What Drove DGX Stock Performance Over the Last Quarter

The +3.2% quarterly rise was propelled by standout Q4 2025 results announced on February 10, featuring revenues of $2.81 billion, up 7.1% year-over-year, and adjusted diluted EPS of $2.42, surpassing expectations. A 7.5% dividend hike to $0.86 per share bolstered investor confidence, alongside Barclays' upgrade to overweight with a $210 target. Broader macroeconomic resilience in healthcare, including sustained testing volumes, offset any regulatory pressures. Positive institutional interest and a consensus "Moderate Buy" rating with an average target of $218 amplified the uptrend, culminating in year-to-date gains exceeding 13%.

Trending AI Robots

Tickeron’s Trending AI Robots page showcases the top-performing AI trading bots from its extensive library of hundreds of algorithms trading thousands of tickers across various markets. This curated section highlights bots with the strongest recent performance and relevance, based on metrics like win rate, average return, and consistency across timeframes such as day trading, swing trading, or long-term strategies. Each bot employs unique approaches, from pattern recognition to momentum signals, enabling users to select tools aligned with their risk tolerance and goals. Explore these leading performers to enhance your trading toolkit today.

DGX Stock Forecast Drivers: What Investors Should Watch Next

Investors should monitor Quest Diagnostics' Q1 2026 earnings on April 21 for insights into revenue growth, margins, and full-year guidance updates. Ongoing industry trends, such as advanced diagnostics adoption and reimbursement policies, could shape sentiment. Macroeconomic factors like healthcare spending and inflation impacts on operations remain key. Strategic developments, including potential partnerships or expansions, alongside analyst revisions and peer performance in diagnostics, warrant attention. Risks from regulatory changes or volume fluctuations in routine testing also merit vigilance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.